In This Article:
NEW YORK, May 07, 2025--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs’ Founder and previous CEO Juan José Chacón-Quirós retired from the role.
"After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision and a mission that is very clear, and execution is paramount to ensure that we accomplish all our goals, including turning EBITDA positive in 2025 and cash flow positive in 2026. Our Founder, Juan José Chacón-Quirós continues as a board member and an integral part of the team, from supporting our continued R&D efforts, to ensuring the adoption of our products and technologies by the plastic surgery community. He will advocate around the world for Establishment Labs and its contributions to women’s health."
"It is an honor to be leading Establishment Labs," added Peter Caldini. "Our company has transformed breast aesthetics and reconstruction globally though innovation and science, and it is in a unique position to do so again as we launch in the United States. We are building an incredibly strong moat in a multibillion-dollar market. Our product suite is one of the most differentiated in medtech, and we are working aggressively to take and expand the market. Most exciting to me is what is in front of us: the chance to marry innovation and best-in-class products with operational excellence so that we can deliver to all our stakeholders, including women, plastic surgeons, and investors."
Fillipo "Peter" Caldini joined Establishment Labs as President in 2024. Previously, he served as the Chief Executive Officer and Director of Acreage Holdings, Inc. from 2020 to 2023 and of Bespoke Capital Acquisition Corp from 2019 to 2020. From 2015 to 2019, Mr. Caldini worked at Pfizer Consumer Healthcare where he was the Regional President for North America and prior to that role, Regional President of EMEA. He worked at Bayer Consumer Healthcare from 2009 to 2014 where he held several roles of increasing responsibility, including Head of Emerging Markets, GM China, and Head of the Nutritionals Strategic Business Unit. Mr. Caldini received his undergraduate degree from Boston University, his MBA from Northeastern University, and a Master’s in International Economics and Management from SDA Bocconi.